Hemostatic Agents Market Disrupted By Collaged Based Hemostats – iCrowdNewswire
Spain Brazil Russia France Germany China Korea Japan

Artificial Intelligence driven Marketing Communications

Sep 11, 2019 12:00 PM ET

Hemostatic Agents Market Disrupted By Collaged Based Hemostats


Hemostatic Agents Market Disrupted By Collaged Based Hemostats

iCrowd Newswire - Sep 11, 2019

Despite the introduction of minimally invasive surgical techniques, invasive procedures still remain a prevalent mode of surgical treatments worldwide. Such procedures require hemostasis, which facilitates the first step in healing wounds, thus resulting in a high demand for the hemostatic agents market, according to a market intelligence report by IndustryARC. Moreover, internal and external bleeding are common occurrences amongst patients who have undergone surgeries or accidents, which further elevates demand for hemostatic agents in hospitals and clinics. According to the report, the hemostatic agents market size will earn revenue amounting to $8,347.9m by the end of 2022, after growing at a CAGR of 7.1% during the forecast period of 2019-2024.

The report titled, ‘Hemostatic Agents Market: By Type (Thrombin, Oxidized Regenerated Cellulose, Combination, Gelatin, Collagen, Fibrin Sealants); By Treatment (Cardiovascular, General, Digestive, Neurological); By End User (Hospitals, Surgical Centers, Nursing Homes) and Geography – Forecast (2019-2024)’, delves into various market forces in order to explain in detail this market’s opportunities such as declining prices of hemostatic agents in the APAC region, increased usage of hemostasis in dentistry, and others. The leading segment of the market is estimated to be hospitals, which will grow at a CAGR of 8.1% through to 2025. This report covers Hemostatic Agents Market Size by type and Application, Hemostatic Agents Market share by top 5 companies and also the market share by start-ups during the forecast period.

View Full Table Of Content Of Hemostatic Agents Market @ https://www.industryarc.com/Report/15189/hemostats-market.html

Report Price (Single User): US $3850

Hemostatic Agents Market: Regional Analysis

According to the report, around 80% Americans suffer from spinal issues and regularly consult hospitals for spinal surgical operations. As a result, the requirement for hemostatic agents is high in the U.S.A. in order to control bleeding during orthopaedic, spinal, and similar surgical procedures. Transplant surgeries of vital organs such as the heart, brain, and liver, which are being performed at an elevated rate due to a steady rise in chronic illnesses, are another contributing factor for this market. Together, these factors have made North America the geographical leader of the global hemostatic agents market with a share of $3,416.7m in 2018.

Hemostatic Agents Market: Market Opportunities And Trends

· The APAC region’s share of the hemostatic agents market is growing at a potentially higher rate owing to emergence of hospital chains in India, China, South Korea, and Japan.

· Collagen-based hemostatic agents have become more popular in the current scenario owing to the growing expense of thrombin-based hemostats.

· Rising aesthetic consciousness among people has resulted in a noticeable rise in dental consumables, which forms an important application segment for the hemostatic agents market, since hemostats are used to control dental haemorrhage and for wound protection.

Talk to one of our sales representative about the full report by providing your details in the link below:

https://www.industryarc.com/support.php?id=15189

Hemostatic Agents Market: Competitive Landscape And Recent Developments

Key companies operating in the global hemostatic agents market are Baxter International Corporation, C.R. Bard Incorporation, B. Braun Melsungen AG, Integra Life Sciences Corporation, Equimedical B.V., Marine Polymer Technologies, Inc., Gelita GmbH, Johnson and Johnson Services Inc., Pfizer Inc., Advanced Medical Solutions Group, Vascular Solutions Inc., Z-Medica LLC, and Mallinckrodt PLC.

· Baxter International Corporation recently launched HDx enabled by Theranova Therapy to provide high-performance hemodialysis treatments.

· C.R. Bard launched Arisa AH which is a 100% plant-based absorbable surgical hemostatic powder.

Related Reports:

Hemodynamic Monitoring Systems Market

https://www.industryarc.com/Report/10602/hemodynamic-monitoring-system-market.html

Varicose Vein Treatment Market

https://www.industryarc.com/Report/17006/varicose-vein-treatment-market.html

Blood Culture Tests Market

https://www.industryarc.com/Report/10633/blood-culture-tests-market.html

About IndustryARC:

IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to [email protected] to discuss more about our consulting services.

Press Release Distributed by The Express Wire

To view the original version on The Express Wire visit Hemostatic Agents Market Disrupted By Collaged Based Hemostats








iCrowdNewswire




Tags:    Wire, Research Newswire, English